After-Hours Movers:

Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) 27% HIGHER; announced today that it has selected a novel development candidate after completing comparative studies in a mouse melanoma model. The candidate represents Sonnet's second bispecific compound integrating Interleukin 12 (IL-12) with the company's Fully Human Albumin Binding (FHAB) platform. The target indications for SON-1410 will be melanoma and renal cancers.

Zoom (NASDAQ: ZM) 11.5% LOWER; reported Q2 EPS of $1.36, $0.34 better than the analyst estimate of $1.02. Revenue for the quarter came in at $1.02 million versus the consensus estimate of $990.96 million. Zoom sees Q3 2022 EPS of $1.07-$1.08, versus the consensus of $1.09. Zoom sees Q3 2022 revenue of $1.015-1.02 billion, versus the consensus of $1.01 billion. You work hard for your money. Park your savings and investments with a broker you can trust. Read More Zoom sees FY2022 EPS of $4.75-$4.79, versus the consensus of $4.67. Zoom sees FY2022 revenue of $4.005-4.015 billion, versus the consensus of $4.01 billion.

Digital Turbine Inc. (NASDAQ: APPS) 7.5% HIGHER; will replace Ligand Pharmaceuticals Inc. (NASDAQ: LGND) in the S&P MidCap 400

Performance Food Group Co. (NYSE: PFGC) 5% HIGHER; will replace TreeHouse Foods Inc. (NYSE: THS) in the S&P MidCap 400.

Galapagos NV (NASDAQ: GLPG) 4.8% HIGHER; announces the planned retirement of CEO Onno van de Stolpe.

StoneCo (NASDAQ: STNE) 4% LOWER; reported Q2 EPS of (R$0.47), versus R$0.54 reported last year. Revenue for the quarter came in at R$613.4 million, versus R$667.4 million reported last year.

ReneSola (NYSE: SOL) 4% LOWER; reported Q2 EPS of $0.10, $0.05 better than the analyst estimate of $0.05. Revenue for the quarter came in at $18.5 million versus the consensus estimate of $20.75 million.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) 3.5% HIGHER; today announced that its partner Gloria Biosciences (GloriaBio) has received approval from Chinas National Medical Products Administration (NMPA) for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody for the treatment of recurrent or refractory classical Hodgkins lymphoma (cHL). GloriaBio has development and commercialization rights in China with respect to zimberelimab through a sublicense agreement with Ligand's licensee Wuxi Biologics Ireland Limited.

Nordson Corp. (NASDAQ: NDSN) 1.8% HIGHER; reported Q3 EPS of $2.42, $0.36 better than the analyst estimate of $2.06. Revenue for the quarter came in at $647 million versus the consensus estimate of $602.66 million. Nordson Corp. raises FY2021 EPS to $7.75-$7.95, versus the consensus of $7.58.